Wednesday, 7 December 2011: 11:10 - 11:30
Costa Maya 2 (Cancún Center)
Pedro Giavina-Bianchi, MD, PhD
,
Clinical Immunology and Allergy, University of Sao Paulo, Sao Paulo, Brazil
Learning Objectives:
Recent novel therapies for allergy are emerging, some of the most promising of which are monoclonal antibodies. Studies have demonstrated the efficacy of omalizumab in asthma treatment, acting in early and late phase of the allergic reaction, improving the quality of life and decreasing the number of exacerbations. Anti-IgE has also being shown to be an effective and safe treatment of therapy-resistant chronic spontaneous urticaria. The aim of this symposium is to discuss the current clinical data as well as possible further indications of omalizumab treatment.
Recent novel therapies for allergy are emerging, some of the most promising of which are monoclonal antibodies. Studies have demonstrated the efficacy of omalizumab in asthma treatment, acting in early and late phase of the allergic reaction, improving the quality of life and decreasing the number of exacerbations. Anti-IgE has also being shown to be an effective and safe treatment of therapy-resistant chronic spontaneous urticaria. The aim of this symposium is to discuss the current clinical data as well as possible further indications of omalizumab treatment.